On February 28, 2019, the US Food and Drug Administration (FDA) released a safety communication that cautioned patients, surgeons, and health care organizations about the use of robotic-assisted surgical systems for the management of breast cancer and other cancers.1 This safety communication cited concerns that evidence to support the use of robotic-assisted surgery for the management of these cancers was limited and may even be associated with shorter long-term survival compared with other surgical approaches.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Sheetz KH, Dimick JB. Is It Time for Safeguards in the Adoption of Robotic Surgery? JAMA. 2019;321(20):1971–1972. doi:10.1001/jama.2019.3736
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: